What is Ukko?
Ukko operates at the intersection of machine learning and immunology, positioning itself as a leader in the precision food technology sector. By utilizing AI-driven protein engineering, the company aims to redesign proteins to eliminate allergic reactions while maintaining their nutritional and functional integrity. This approach addresses a critical market gap for consumers suffering from food sensitivities, effectively transforming how the food industry approaches allergen management. With a robust intellectual property portfolio and a focus on scalable biotechnology, Ukko is well-positioned to disrupt traditional food manufacturing processes and improve global health outcomes through science-backed innovation.
How much funding has Ukko raised?
Ukko has raised a total of $47.7M across 2 funding rounds:
Series A
$7.7M
Series B
$40M
Series A (2017): $7.7M with participation from Izhar Armony, Slow Ventures, Khosla Ventures, Innovation Endeavors, and Marc Benioff
Series B (2021): $40M led by Continental Grain Company, Leaps by Bayer, Skyviews Life Science, Fall Line Capital, and Peak Bridge Ventures
Key Investors in Ukko
Continental Grain Company
A global investor and operator with a deep history in the food, agribusiness, and commodities sectors, providing strategic oversight and industry expertise.
Fall Line Capital
An investment firm focused on the intersection of farmland management and agricultural technology, dedicated to enhancing productivity through innovative capital deployment.
Khosla Ventures
A prominent venture capital firm known for backing early-stage companies that utilize transformative technology to solve significant global problems.
What's next for Ukko?
With the recent capital injection, Ukko is expected to accelerate its research and development pipeline, focusing on the clinical validation of its lead candidates. The company's strategic roadmap likely includes expanding its computational platform to address a broader range of food allergens and potentially entering into partnerships with major food conglomerates to integrate its technology into mainstream supply chains. As Ukko transitions from a research-heavy startup to an enterprise-level biotech player, the focus will shift toward regulatory milestones and the commercialization of its first-generation hypoallergenic ingredients. This growth phase will be critical in establishing Ukko as the standard-bearer for safe, personalized nutrition in the global marketplace.
See full Ukko company page
